Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 4/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 8/20 | 0.35 |
| ▸ | TCF7L2 | Q9NQB0 | 8/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622067 | 1.00 | CHEK2 (0.50) | CHEK2JAK2JAK3PTGER4CTNNB1 | |
| SCHEMBL1624098 | 0.96 | CHEK2 (0.47) | CHEK2JAK2JAK3PTGER4CTNNB1 | |
| SCHEMBL1624103 | 0.96 | CHEK2 (0.47) | CHEK2JAK2JAK3PTGER4CTNNB1 | |
| Hydrochloric Acid SCHEMBL1624148 | 0.95 | CHEK2 (0.46) | CHEK2JAK2JAK3PTGER4CTNNB1 | |
| Hydrochloric Acid SCHEMBL1624151 | 0.95 | CHEK2 (0.46) | CHEK2JAK2JAK3PTGER4CTNNB1 | |
| SCHEMBL1624158 | 0.90 | CHEK2 (0.51) | CHEK2CTNNB1TCF7L2MAPTKDM4E | |
| SCHEMBL1624156 | 0.90 | CHEK2 (0.51) | CHEK2CTNNB1TCF7L2MAPTKDM4E | |
| SCHEMBL1624869 | 0.89 | CHEK2 (0.49) | CHEK2CTNNB1TCF7L2P2RX3P2RX2 | |
| SCHEMBL1624865 | 0.89 | CHEK2 (0.49) | CHEK2CTNNB1TCF7L2P2RX3P2RX2 | |
| Hydrochloric Acid SCHEMBL1623774 | 0.88 | CHEK2 (0.48) | CHEK2CTNNB1TCF7L2P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-7928107-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-19 | — | — | US | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | CHEK2 2935/4885JAK2 3157/4885JAK3 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.